GPI to launch first and only rapid value assessment and price prediction platform at World EPA Congress

GPI will be attending the EPA conference (stand 15), showcasing our innovative solutions and the new platform, based on the horizon methodology.

  • The risk and cost involved with drug development has expedited in recent years and will continue to increase, creating more pressure for faster and more agile solutions
  • The horizon methodology provides and analytics powered solution for rapid value assessment and price prediction unlike any other on the market
  • GPI CEO, Preeti Patel will be presenting on day two at 3:15pm, on the rare diseases track and will be available throughout the conference on stand 15.

Tuesday 21st February, London, UK: Global Pricing Innovations (GPI), a leader in market access and commercial strategy solutions, will be attending the World EPA Congress, held at the RAI Amsterdam, on 21st – 23rd March 2023. GPI will present the new rapid value assessment and price prediction horizon methodology platform, on stand 15.

The horizon platform is a step change in how pharma and biotech will make faster asset decisions, earlier on in the lifecycle. The cost of bringing an asset to market has doubled from $1.3bn in 2013 to $2.4bn in 20191, further demonstrating the risk associated with investing in new drug development. This will only continue to increase and the current methods for price and access research are simply not sustainable.

The horizon platform delivers rapid value assessment and price prediction to inform: portfolio strategy and prioritization, early investment decisions, strategic price and access planning leading up to launch and price revisions throughout the lifecycle.

“We’re really excited to be able showcase our latest innovation, in-person, for the first time.” Says Preeti Patel, GPI CEO. “The horizon methodology is a game-changer for our industry as the only platform solution on the market that delivers rapid value assessment and price prediction. We are extremely excited to showcase it at the conference.”

EPA Congress attendees will be able to see first-hand how the platform works on the GPI stand throughout and will be able to discuss how it can support their assets and improve outcomes.

GPI’s CEO, Preeti Patel, will be presenting on the Rare Diseases track, discussing ‘how technology is solving the orphan drugs problem’. Join her on day two of the conference, Wednesday 22nd March at 3:15pm, to find out more about how to keep up with rapid innovation. The presentation will draw upon insights from the data analytics platform, GPI pulse™ and how the horizon methodology will also add value.

GPI delivers innovative price and market access solutions through agile work streams, adapting technology and services to respond to market trends. GPI’s investment in R&D has led to an expanding portfolio of technology-based solutions, centred around robust, reliable data. At World EPA Congress, both technological based solutions, GPI pulse™ and the horizon methodology will be demonstrated, in addition to our bespoke consulting capabilities.

Join us on our stand (15), to hear more about the development of the horizon methodology, or GPI pulse™ data analytics platform. Our representatives will be on hand throughout to discuss how GPI’s service and technological-based solutions are driving intelligent and agile market access decision making.


1Ten years on measuring return on pharma innovation. Deloitte.

About GPI

Global Pricing Innovations is a market leader in price and market access insights, providing innovative approaches and solutions to the biopharma industry.

Headquartered in London, GPI provide best-in-class data analytics platform and consulting services, providing evidence-based decision support helping clients to make better investment decisions and with the horizon methodology, has the only value assessment and price prediction platform on the market.

As a team of leading domain specialists, GPI provide high quality, curated and rapid insights.  We are ideally placed to make recommendations on global drug pricing strategy, market access optimisation, asset evaluation, value perception and payer analytics.

GPI’s suite of technology and bespoke service offerings are powered by GPI pulse™, a solution that harnesses the power of technology, data, and collective expertise to produce rapid insights. The team of market access professionals, pharmacists and data specialists leverage the technology to create truly bespoke price and market access strategies, saving clients hours of paid consultancy.

To find out more about GPI, visit

Share this News:

Press Release (1)